Lentiviral vector expresses protein for up to four years in trial.
Phase II trial shows Clearside’s CLS-TA safe and effective in noninfectious uveitis.
Experience with six patients who have had this device implanted.
This biological agent targets mutations in genes that mediate visual transduction.
A deeper dive into how this Tie-2 activator stabilizes the retinal vasculature.
A review of compelling presentations in retina from ARVO.
A closer look at combination therapy and CNV.
A real-life experience with the only retinal prosthesis approved by the FDA and Health Canada.
Lead investigator provides details on parallel trials of lampalizumab.
A host of trials are trying to answer this question. Here’s what they’ve found so far.
What we can take from the study and apply in our clinics.